基于合并症与筛查史计算结直肠癌筛查的停止年龄
该研究利用Microsimulation Screening Analysis-Colon模型,按性别、合并症状态和筛查史评估每两年一次粪便免疫化学检测筛查的危害与获益,以平均健康人群完美筛查史者76岁停止筛查的阈值为参照,确定最佳停止筛查年龄。结果显示最佳停止年龄从具有完美筛查史且合并症严重者的66岁及以下,到无筛查史健康女性的90岁和无筛查史健康男性的88岁不等。
要点
- 完美筛查史者76岁时需筛查157名女性和108名男性才能每1000人获得1个生命年。
- 无合并症且无筛查史的女性可初始筛查至90岁,男性至88岁。
- 筛查依从性提高或合并症增加时,最佳停止筛查年龄降低;严重合并症且完美筛查史者应66岁或更早停止筛查。
核心结论
- 基于危害-获益平衡,结直肠癌筛查的最佳停止年龄范围为66岁(具有完美筛查史的不健康个体)至90岁(无既往筛查的健康个体)。
- 这些发现可用于协助患者和临床医生做出筛查参与决策。
研究设计与样本
- 使用Microsimulation Screening Analysis-Colon模型,按性别、合并症状态和筛查史估算每两年一次粪便免疫化学检测筛查的危害与获益。
- 以平均健康人群完美筛查史者从50岁起每两年一次粪便免疫化学检测筛查至76岁停止所提供阈值为参照,基于每1000名筛查个体获得1个额外生命年所需的增量筛查人数确定最佳停止筛查年龄。
主要发现
- 对于76岁者,具有完美筛查史的女性需筛查157人、男性需筛查108人才能每1000名筛查个体获得1个生命年。
- 无合并症且无筛查史的女性可初始筛查至90岁,无筛查史男性可初始筛查至88岁,之后才达到该平衡。
- 随着筛查依从性提高或合并症增加,最佳停止筛查年龄降低,以至于无论性别,具有严重合并症和完美筛查史的个体应66岁或更早停止筛查。
临床怎么用
- 这些发现可用于协助患者和临床医生做出筛查参与决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Routine screening for colorectal cancer typically is recommended until age 74 years. Although it has been proposed that a screening stop age could be determined based on sex and comorbidity, less is known about the impact of screening history. We investigated the effects of screening history on the selection of an optimal age to stop screening. METHODS: We used the Microsimulation Screening Analysis-Colon model to estimate the harms and benefits of screening with biennial fecal immunochemical tests by sex, comorbidity status, and screening history. The optimal screening stop age was determined based on the incremental number needed for 1 additional life-year per 1000 screened individuals compared with the threshold provided by stopping screening at 76 years in the average-health population with a perfect screening history (attended all required screening, diagnostic, and follow-up tests) to biennial fecal immunochemical testing from age 50 years. RESULTS: For persons age 76 years, 157 women and 108 men with a perfect screening history would need to be screened to gain 1 life-year per 1000 screened individuals. Previously unscreened women with no comorbid conditions and no history of screening could undergo an initial screening through 90 years, whereas unscreened men could undergo initial screening through 88 years, before this balance is reached. As screening adherence improved or as comorbidities increased, the optimal age to stop screening decreased to a point that, regardless of sex, individuals with severe comorbidities and a perfect screening history should stop screening at age 66 years or younger. CONCLUSIONS: Based on the harm-benefit balance, the optimal stop age for colorectal cancer screening ranges from 66 years for unhealthy individuals with a perfect screening history to 90 years for healthy individuals without prior screening. These findings can be used to assist patients and clinicians in making decisions about screening participation.
引用
- Cenin DR, Tinmouth J, Naber SK, et al. Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. Clin Gastroenterol Hepatol. 2020. PMID: 32450362. doi:10.1016/j.cgh.2020.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。